Welcome to our dedicated page for Oric Pharmaceuticals SEC filings (Ticker: ORIC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ORIC Pharmaceuticals, Inc. filings document a Nasdaq-listed clinical-stage oncology company focused on therapeutic resistance in cancer. Its 8-K reports furnish financial results and operational updates, clinical presentation materials for rinzimetostat (ORIC-944) and enozertinib (ORIC-114), and Regulation FD investor presentation slides.
Other disclosures cover ORIC's common stock, shelf registration and at-the-market share sales, prospectus supplement activity, emerging growth company status, and annual meeting proxy matters. The proxy record addresses stockholder voting, board governance, compensation oversight, and equity incentive arrangements, including inducement grants under Nasdaq listing rules.
ORIC Pharmaceuticals reported fourth quarter and full-year 2025 results alongside major clinical progress in prostate and lung cancer. The company ended December 31, 2025 with $392.3 million in cash, cash equivalents and investments and expects this to fund its operating plan into the second half of 2028.
ORIC raised a total of $264 million in 2025 from a private placement and its ATM program, plus an additional $20.0 million afterward. Full-year R&D expenses were $109.8 million and G&A expenses were $33.2 million, leading to a net loss of $129.5 million, or $1.47 per share.
Clinically, rinzimetostat showed promising Phase 1b data in metastatic castration-resistant prostate cancer, with 55% of patients achieving PSA50 responses and 59% achieving ctDNA clearance, supporting plans for a Phase 3 trial in 1H 2026. Enozertinib generated strong systemic and intracranial responses in EGFR exon 20 and EGFR PACC-mutated NSCLC, with first-line data updates expected in the second half of 2026.
ORIC Pharmaceuticals’ institutional holders led by Venrock Healthcare Capital Partners report a 5.8% beneficial stake in the company’s common stock. The group, including several Venrock funds and individuals Nimish Shah and Bong Koh, collectively owns 5,676,230 ORIC common shares as of December 31, 2025.
The ownership is spread across VHCP III, VHCP Co-Investment III, and VHCP EG funds, with control entities VHCP Management III and VHCP Management EG. The percentage is calculated using 97,389,279 shares outstanding as of November 5, 2025, from ORIC’s Form 10-Q, and the group certifies the holdings are not for changing or influencing control.
BlackRock, Inc. has disclosed a significant passive ownership position in ORIC PHARMACEUTICALS INC common stock. BlackRock reports beneficial ownership of 5,473,145 shares, representing 5.6% of the outstanding common stock as of the reporting date of 12/31/2025.
BlackRock has sole power to vote 5,388,358 shares and sole power to dispose of 5,473,145 shares, with no shared voting or dispositive power. The holdings are attributed to certain BlackRock business units, and various underlying clients have the right to receive dividends or sale proceeds, but no individual client holds more than five percent of ORIC’s total common shares. BlackRock states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of ORIC.
Oric Pharmaceuticals director Richard A. Heyman reported planned stock sales under a Rule 10b5-1 trading plan shared with RAHD Capital, LLC. On January 16, 2026, he sold 3,500 shares of common stock directly at a weighted average price of $12.0046, leaving 41,800 shares held directly. The same day, 3,200 additional shares were sold indirectly at the same weighted average price, with 213,072 shares then held of record by RAHD Capital, LLC, over which he has voting and investment power. In total, the filing notes a weighted average price for 6,700 shares sold in a price range of $12.00 to $12.03.
A holder of ORIC common stock has filed a notice to sell 6,400 shares under Rule 144. The planned sale is through J.P. Morgan Securities LLC on the Nasdaq, with an indicated aggregate market value of $76,800 and the class having 97,389,279 shares outstanding.
The shares to be sold were originally acquired on 07/31/2015 through a stock option exercise from the issuer, paid in cash on the same date. The filer represents that they do not know of any material adverse, nonpublic information about ORIC’s current or future operations.
ORIC Pharmaceuticals filed a notice that a shareholder plans to sell 7,000 shares of common stock through J.P. Morgan Securities LLC on Nasdaq, with an aggregate market value of $84,000. The filing lists 97,389,279 shares of common stock outstanding. The shares to be sold were acquired on 08/25/2016 by exercising stock options for cash on that same date.
Oric Pharmaceuticals director files insider transaction report for new stock options. Director Lori Anne Kunkel reported receiving a stock option covering 40,000 shares of Oric Pharmaceuticals common stock on January 2, 2026. The option has an exercise price of $8.17 per share and is held as a derivative security with direct ownership. According to the vesting terms, 1/12 of the shares subject to the option vest on each monthly anniversary of January 2, 2026, resulting in full vesting over one year. The option is scheduled to expire on January 1, 2036, if not exercised earlier.
Oric Pharmaceuticals director Steven L. Hoerter reported a new stock option grant for 40,000 shares of common stock. The option, with an exercise price of $8.17 per share, was awarded on January 2, 2026 and is held directly. It is scheduled to vest in equal monthly installments, with 1/12 of the shares vesting on each one-month anniversary of January 2, 2026, until fully vested. The option expires on January 1, 2036, giving the director a long-dated right to purchase Oric common shares at the fixed exercise price.
Oric Pharmaceuticals, Inc. director Richard A. Heyman reported receiving a stock option grant for 40,000 shares of common stock. The option has an exercise price of $8.17 per share and expires on January 1, 2036. According to the vesting schedule, 1/12 of the shares under the option vest on each monthly anniversary of January 2, 2026, resulting in full vesting over one year. Following this grant, he beneficially owns 40,000 stock options directly.
Oric Pharmaceuticals Chief Financial Officer Dominic Piscitelli reported new equity awards. On January 2, 2026, he received a stock option covering 206,500 shares of Oric common stock with an exercise price of $8.17 per share. According to the vesting terms, 25% of these option shares vest on January 2, 2027, and the remaining shares vest in equal monthly installments over the following 36 months.
He was also granted 34,500 restricted stock units (RSUs), each representing a right to receive one share of Oric common stock. One-third of these RSUs vests on each of December 15, 2026, December 15, 2027, and December 15, 2028. Both the option and RSUs are reported as directly owned and were acquired as part of his compensation.